Credit Suisse AG grew its holdings in Cellectis SA (NASDAQ:CLLS) by 9.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 420,667 shares of the biotechnology company’s stock after purchasing an additional 35,363 shares during the quarter. Credit Suisse AG owned approximately 1.01% of Cellectis worth $11,871,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. FMR LLC grew its position in shares of Cellectis by 18.0% in the second quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock valued at $119,949,000 after purchasing an additional 647,164 shares during the last quarter. JBF Capital Inc. acquired a new stake in shares of Cellectis in the second quarter valued at approximately $1,697,000. ARK Investment Management LLC grew its position in shares of Cellectis by 178.8% in the second quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock valued at $6,910,000 after purchasing an additional 156,666 shares during the last quarter. BlackRock Inc. grew its position in shares of Cellectis by 259.7% in the second quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock valued at $12,552,000 after purchasing an additional 320,340 shares during the last quarter. Finally, Vident Investment Advisory LLC grew its position in shares of Cellectis by 30.3% in the second quarter. Vident Investment Advisory LLC now owns 80,527 shares of the biotechnology company’s stock valued at $2,278,000 after purchasing an additional 18,730 shares during the last quarter. Institutional investors and hedge funds own 27.68% of the company’s stock.
Shares of CLLS opened at $20.25 on Friday. Cellectis SA has a 1 year low of $20.15 and a 1 year high of $38.85.
WARNING: “Credit Suisse AG Grows Stake in Cellectis SA (CLLS)” was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://baseballnewssource.com/2018/12/08/credit-suisse-ag-grows-stake-in-cellectis-sa-clls/3063989.html.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Further Reading: How Do You Calculate Return on Equity (ROE)?
Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.